| answer text |
<p>In June 2013 the National Institute for Health and Care Excellence (NICE) issued
an updated clinical guideline on familial breast cancer which includes recommendations
on the use of tamoxifen and raloxifene outside their licensed indications for the
prevention of cancer in specific groups of women at high and moderate risk of breast
cancer.</p><p> </p><p> </p><p> </p><p>NICE’s clinical guidelines represent best practice
and we expect commissioners to take their recommendations into account when designing
services and making commissioning decisions for their healthcare population.</p><p>
</p><p><strong> </strong></p><p> </p><p>Information on the number of women treated
with tamoxifen and raloxifene for the treatment or prevention of breast cancer is
not collected centrally.</p><p> </p>
|
 |
